UK-Switzerland strike trade deal with first-of-its-kind pharma rules

An enhanced agreement between the two countries cements existing protections for pharma innovators and is being hailed by the industry as a boost for investment and research.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Regulation & Industry

Where Big Pharma is betting big in the M&A boom

29 July 2026 Dealmaking is at a record pace, but not every asset is in play. So what are the therapy areas commanding the fiercest bidding wars and what’s to come?

Regulation & Industry

Buying the brains: Why is Big Pharma shopping for innovation?

27 July 2026 With billions in revenue set to disappear as patents expire, pharmaceutical giants are racing to acquire their way out of trouble. But are there other drivers behind the surge—and how long can the momentum last?

Regulation & Industry

Trump slaps 100% tariff on generic drugs in US manufacturing push

23 July 2026 Generic drug manufacturers face huge penalties if they fail to relocate production to the US within two years, with India among the countries expected to be hardest hit.

More features

K&L Gates expands European practice with Munich team hire

Exclusive: Winston Taylor’s UK head of IP on pitching $1.75bn firm’s ‘humble, but lethal’ practice

Insulet asks Fed Circ to rehear $59.4m trade secret reversal

Arnold & Porter adds firepower to ITC practice with new partner hire

USPTO director steps into Sun Pharma’s PTAB-ITC clash

USPTO appoints new acting commissioner for patents

European court strikes down hearing aid sensor patent

Where Big Pharma is betting big in the M&A boom

UK-Switzerland strike trade deal with first-of-its-kind pharma rules

More on this story

Editor's picks

Editor's picks

More features